RE:RE:RE:RE:1.2 M in cash....anyone know how far that will go :) This This low pp is a bridge pp to the FDA Breakthrough's response. No doubt.
TLT is doing the right things, in the right order, at the right moment. Up to big pharmas to confirm their interest.
Highest efficacy % translate into larger market shares for the one that will want to jv with us.
Very interesting to see Dr. Kamat presenting our treatment @AUA on p. 11 of the latest corporate presentation. TLT is clearly engaged in giving our treatment the highest visibility to our core clientele; the urologists.
By the way, for immunotherapies, an oncologist has to be involved in the picture, on top of a urologist. Our treatment doesn't require the involvement of an oncologist. So a much leaner process for the patients, faster availability as 2 professionals don't have to synch themselves together to handle a patient's case.